Elbasvir/grazoprevir for treatment of chronic hepatitis C virus infection.
Hepatitis C is the leading cause of progressive liver fibrosis worldwide and results in cirrhosis, liver cancer, liver failure and death. Successful treatment for hepatitis C virus (HCV) has rapidly evolved in recent years to a well-tolerated, highly efficacious all-oral therapy. Elbasvir/grazoprevir (Zepatier) is the newest of the oral combinations of HCV direct-acting agents that was approved by the US Federal Drug Administration. This review focuses on the pharmacology, mechanism of action and clinical trial data that support the use of this new combination treatment for HCV infection. The data suggest that Zepatier offers an excellent treatment efficacy, safety and tolerability in HCV treatment naïve and experienced patients and those with and without cirrhosis across multiple genotypes. Also, it has the selective advantage of safety and efficacy in patients with renal disease, especially in those with end-stage renal disease and/or hemodialysis patients.
Department of Medicine, Augusta University, Augusta, GA, USA.
Chandana
C
Papudesu
Division of Infectious Diseases and Institute of Human Virology, University of Maryland School of Medicine, Room N359, 725 West Lombard Street, Baltimore, MD, 21201, USA.
Shyamasundaran
S
Kottilil
Division of Infectious Diseases and Institute of Human Virology, University of Maryland School of Medicine, Room N359, 725 West Lombard Street, Baltimore, MD, 21201, USA. sbagchi@som.umaryland.edu.
Shashwatee
http://orcid.org/0000-0002-8043-8605
S
Bagchi
D000577:Amides; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001572:Benzofurans / Q000008:administration & dosage / Q000627:therapeutic use*; D002219:Carbamates; D003521:Cyclopropanes; D004338:Drug Combinations; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D011810:Quinoxalines / Q000008:administration & dosage / Q000627:therapeutic use*; D013449:Sulfonamides; D047029:Lactams, Macrocyclic
D000577:Amides; D000998:Antiviral Agents; D001572:Benzofurans; D002219:Carbamates; D003521:Cyclopropanes; D004338:Drug Combinations; D007093:Imidazoles; D011810:Quinoxalines; D013449:Sulfonamides; C578009:grazoprevir; D047029:Lactams, Macrocyclic; C000589335:elbasvir
Direct-acting antivirals; Hepatitis C virus; Interferon-free treatment; Sustained virological response